Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
Syncope recurrence can better be predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope
Clinical Electrophysiology Laboratory, Cardiology Division, Department of Medicine, Hospital of the Philipps-University of Marburg Marburg, Germany
revised 20 March 1997; accepted 26 March 1997.
Correspondence: Wolfram Grimm, MD, Philipps-University Marburg, Department of Cardiology, Baldingerstraße, 35033 Marburg, Germany
Abstract
BACKGROUND: Head-up tilt testing is widely used in the evaluation of patients with suspected neurally mediated syncope. Although it remains unclear which patients require medical therapy to prevent recurrent syncope, most centres initiate empiric medical therapy in all patients in whom neurally mediated syncope has been diagnosed. To determine the natural history of this condition, we followed 80 untreated patients.
METHODS: All 80 study patients fulfilled the following inclusion criteria: (1) 
1 syncope in the upright position, (2) absence of structural heart disease, (3) unremarkable work-up for other known causes of syncope. Thirty-nine patients had a history of one episode of syncope (group A) and 412 episodes of syncope (group B). Head-up tilting was performed in all patients at 60° for a maximum of 45 min without medical provocation (‘Westminster Protocol’).
RESULTS: Suspected neurally mediated syncope could be reproduced by tilt testing in four of 39 patients from group A vs 10 of 41 patients from group B (10% vs 24%, P=0·1). Independent of the result of head-up tilt testing, all patients were prospectively followed without medical therapy. During 23±8 months follow-up, syncope recurred in four of 39 group A patients vs 22 of 41 group B patients (10% vs 54%, P<0·05). The incidence of syncope during follow-up was not significantly different between patients with and without positive baseline tilt test (43% vs 30%, P=ns).
CONCLUSIONS: (1) 90% of patients with a single episode of syncope remain free of recurrent syncope without medical therapy irrespective of the result of tilt testing. (2) About half of patients with a history of 2 syncopal episodes have recurrent syncope and, thus, may be appropriate candidates for prophylactic medical therapy. (3) Although head-up tilt testing at 60° for up to 45 min does not appear to be useful to predict recurrent syncope in untreated patients, it is still a useful test in its evaluation.
Key Words: Neurally mediated syncope • head-up tilt table testing
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Brignole, R. Sutton, C. Menozzi, R. Garcia-Civera, A. Moya, W. Wieling, D. Andresen, D. G. Benditt, N. Grovale, T. De Santo, et al. Lack of correlation between the responses to tilt testing and adenosine triphosphate test and the mechanism of spontaneous neurally mediated syncope Eur. Heart J., September 2, 2006; 27(18): 2232 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brignole, R. Sutton, C. Menozzi, R. Garcia-Civera, A. Moya, W. Wieling, D. Andresen, D. G. Benditt, P. Vardas, and for the International Study on Syncope of Uncertai Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope Eur. Heart J., May 1, 2006; 27(9): 1085 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sheldon, S. Connolly, S. Rose, T. Klingenheben, A. Krahn, C. Morillo, M. Talajic, T. Ku, F. Fouad-Tarazi, D. Ritchie, et al. Prevention of Syncope Trial (POST): A Randomized, Placebo-Controlled Study of Metoprolol in the Prevention of Vasovagal Syncope Circulation, March 7, 2006; 113(9): 1164 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K A McLeod Syncope in childhood Arch. Dis. Child., April 1, 2003; 88(4): 350 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sheldon, S. Rose, S. Connolly, and on behalf of the POST investigators Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope: Rationale and study design Europace, January 1, 2003; 5(1): 71 - 75. [Abstract] [PDF]
|
|
|
|
|
|
F. Colivicchi, F. Ammirati, A. Biffi, L. Verdile, A. Pelliccia, and M. Santini Exercise-related syncope in young competitive athletes without evidence of structural heart disease. Clinical presentation and long-term outcome Eur. Heart J., July 2, 2002; 23(14): 1125 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kouakam, G. Vaksmann, E. Pachy, D. Lacroix, C. Rey, and S. Kacet Long-term follow-up of children and adolescents with syncope; predictor of syncope recurrence Eur. Heart J., September 1, 2001; 22(17): 1618 - 1625. [Abstract] [PDF]
|
|
|
|
 |
|
 K. A McLeod CONGENITAL HEART DISEASE: Dizziness and syncope in adolescence Heart, September 1, 2001; 86(3): 350 - 354. [Full Text] [PDF]
|
|
|
|
|
|
R. Sheldon and S. Rose Components of clinical trials for vasovagal syncope Europace, January 1, 2001; 3(3): 233 - 240. [Abstract] [PDF]
|
|
|
|
|
|
A. Raviele, M. Brignole, R. Sutton, P. Alboni, P. Giani, C. Menozzi, and A. Moya Effect of Etilefrine in Preventing Syncopal Recurrence in Patients With Vasovagal Syncope : A Double-Blind, Randomized, Placebo-Controlled Trial Circulation, March 23, 1999; 99(11): 1452 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sagrista-Sauleda, B. Romero, G. Permanyer-Miralda, A. Moya, T. Rius-Gelabert, L. Mont Girbau, and J. Soler-Soler Clinical usefulness of head-up tilt test in patients with syncope and intraventricular conduction defect Europace, January 1, 1999; 1(1): 63 - 68. [Abstract] [PDF]
|
|